» Articles » PMID: 15282420

Current Applications for Nicardipine in Invasive and Interventional Cardiology

Overview
Date 2004 Jul 30
PMID 15282420
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Interventional coronary procedures, such as rotational atherectomy and coronary artery bypass graft (CABG) stenting, are associated with a risk of postoperative vasoconstriction, which can lead to sequelae that produce morbidity and even death. Vasodilators, such as calcium channel blockers, sodium nitroprusside and adenosine, are often administered to prevent or reverse these sequelae, and have proven effective for this purpose. The injectable dihydropyridine calcium channel blocker, nicardipine, has several unique properties that make it an effective option for preventing and/or reversing microvascular or conductance vessel vasoconstriction. In this review, we describe the evidence-based uses of nicardipine injection in interventional cardiology and cardiac catheterization procedures. In comparison to other calcium channel blockers, nicardipine injection appears to be potentially safer, easier to administer and capable of producing a more predictable response. This drug has potential advantages in preventing or reversing the no-reflow phenomenon that sometimes occurs after interventions in coronary bypass grafts. Nicardipine may also be effective when administered in a flush solution with other drugs during rotational atherectomy and clot debulking with or without distal protection devices. It also can control the hypertension that occurs after sternotomy and cardiac surgery, and in the cardiac catheterization laboratory. In summary, the dihydropyridine calcium channel blocker, nicardipine, has a wide range of useful applications during cardiovascular interventions.

Citing Articles

Management of no Reflow during Percutaneous Transcoronary Angioplasty with Catheter-Directed Intracoronary Thrombolysis: A Retrospective Observational Study.

Singh R, Singla S, Singla A, Manchanda S, Kaur M Int J Appl Basic Med Res. 2023; 12(4):260-264.

PMID: 36726658 PMC: 9886142. DOI: 10.4103/ijabmr.ijabmr_407_22.


Myocardial preservation during primary percutaneous intervention: It's time to rethink?.

Yadav R, Yadav S, Goswami K, Yadav G Indian Heart J. 2021; 73(4):395-403.

PMID: 34474749 PMC: 8424360. DOI: 10.1016/j.ihj.2021.07.008.


Initiate Danhong Injection before or after percutaneous coronary intervention for microvascular obstruction in ST-elevation myocardial infarction (DIRECTION): study protocol for a randomized controlled trial.

Zhang X, Tian G, Shi Z, Sun Y, Hu J, Jiang Y Trials. 2020; 21(1):48.

PMID: 31915046 PMC: 6950857. DOI: 10.1186/s13063-019-3947-6.


Influence of tangential stress on mechanical responses to vasoactive agents in human saphenous vein with and without perivascular adipose tissue.

Ford C, Mong K, Tabrizchi R Can J Cardiol. 2006; 22(14):1209-16.

PMID: 17151770 PMC: 2569069. DOI: 10.1016/s0828-282x(06)70961-8.


Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Curran M, Robinson D, Keating G Drugs. 2006; 66(13):1755-82.

PMID: 16978041 DOI: 10.2165/00003495-200666130-00010.